BMO Capital Maintains Outperform on Structure Therapeutics, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Structure Therapeutics (NASDAQ:GPCR) and raises the price target from $83 to $100.
June 07, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained its Outperform rating on Structure Therapeutics and raised the price target from $83 to $100, indicating strong confidence in the company's future performance.
The raised price target and maintained Outperform rating from a reputable analyst suggest positive sentiment and expected growth for Structure Therapeutics, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100